

## References – Spiriva

1. Spiriva product monograph, November 6, 2002.
2. Hvizdos KM, Goa KL. Tiotropium bromide. *Drugs* 2002;62(8):1195-1203.
3. van Noord JA, Bantje TA, Eland ME et al. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. *Thorax* 2000;55(4):289-94.
4. Vincken W, van Noord JA, Greefhorst APM et al. Improved health outcomes in patients with COPD during 1 yr=s treatment with tiotropium. *Eur Resp J* 2002;19(2):209-16.
5. Donohue JF, van Noord JA, Bateman ED et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. *Chest* 2002;122(1):47-55.
6. Pauwels RA, Buist AS, Calverley PMA et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO global initiative for chronic obstructive lung disease (GOLD) workshop summary. *Am J Respir Crit Care Med* 2001;163:1256-76.
7. Gray J (ed). *Therapeutic Choices*, 3<sup>rd</sup> edition. Canadian Pharmacists Association, 2000; Ottawa.
8. Welbanks L, editor. *Compendium of Pharmaceuticals and Specialties*, 37<sup>th</sup> Edition. Canadian Pharmacists Association, 2002, Ottawa.
9. CCOHTA. Tiotropium: A potential replacement for ipratropium in patients with COPD. *Issues in Emerging Health Technologies* 2002;35:1-4.
10. Skukla VK, et al. Long-acting B2-agonists for maintenance therapy of stable chronic pulmonary obstructive disease: a systematic review. *CCOHTA Technology Report* 2002;27:1-40.